Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Seretide at all doses and devices is indicated in the regular treatment of asthma for patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.
The Seretide 50/500mg Diskus is also licensed for regular use in COPD for patients with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. For further indication details please refer to the SPC
Over 102.49 million patient treatment years and counting[1]
Three strengths in two different devices: metered dose inhaler (MDI) and dry powder inhaler (DPI)[2]
Studied in over 90 clinical trials[3]
References:
- Data on file: RF/SFC/0008/15(2) Dec 2016. This figure is taken from the Seretide DSUR 2016N296472 with Patient Exposure as of June 2016 and is an estimate based on IMS heath data.
- Seretide SPC, accessed January 2018.
- WHO clinical trials search portal, accessed March 2017.
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Seretide, Diskus and Evohaler are a registered trademarks of the GlaxoSmithKline group of companies
